BloodSurf 2016: Blood-Biomaterial Interactions

 描述（由申请人提供）：生物材料诱导的血栓形成是用于治疗心血管和血管疾病的所有血液接触医疗器械的首要临床问题，从相对简单的导管、球囊和支架到复杂的机械系统，如心室辅助装置（VAD）。虽然抗血栓形成和抗血小板药物（如肝素和氯吡格雷（Plastime））通常用于抑制接受此类器械治疗的患者的生物材料诱导血栓形成，但这些类型的药物会全身抑制凝血，这可能导致其他临床显著的出血相关并发症。抗血栓生物材料的开发将为心血管和血管疾病提供更有效的治疗，这将消除或至少大大减少对使用全身抗血栓治疗的需求。然而，对合成材料与血液接触后血栓形成反应的具体机制的了解有限，继续阻碍心血管和血管疾病的新临床器械和治疗方法的开发。解决这个问题需要来自不同领域的研究人员和实践者的努力，特别是，这需要生物学家、化学家、物理学家和工程师与临床实践者之间的密切互动。BloodSurf 2016研讨会的具体目的（2016年9月13日至16日，巴布森行政会议中心，韦尔斯利，MA）是汇集来自这些各自学科的专家沿着与学生和博士后研究员谁拥有共同的兴趣，在血栓的发展，耐生物材料四天沉浸在介绍和讨论的关键需求和研究方向的医疗器械的发展，改善血液相容性。认识到血小板在介导血液对生物材料的反应中的关键作用，以及在一般止血和血栓形成社区中与科学家和临床医生更紧密结合的必要性，本次研讨会将与由Alan D.迈克尔逊，血小板研究主任和医学教授，哈佛医学院，和大卫瓦伦博士，血液学教授，耶路撒冷希伯来大学。Plastics国际研讨会将在BloodSurf 2016之后举行，包括为期一天的联合会议。由于BloodSurf 2016代表了一个独特的会议，福尔斯每年举行的专业会议的正常安排之外，要求资金支持，以抵消出席我们的一套16受邀演讲者的费用，以及提供八个学生/博士后旅行奖（其中四个将预留给妇女，少数民族和残疾人的支持）。 叙述：生物材料诱导的血栓形成是所有用于治疗心血管和血管疾病的血液接触医疗器械常见的头号临床问题。BloodSurf 2016研讨会将汇集对改善血液接触医疗器械的血液相容性感兴趣的领先科学家、工程师和临床医生，进行为期四天的重点演讲和讨论。资金支持要求抵消旅费为我们的16位特邀演讲者，并提供八个学生和博士后研究员参加本次研讨会的旅行奖。

 DESCRIPTION (provided by applicant): Biomaterial-induced thrombus formation is the number one clinical problem common to all blood-contacting medical devices that are used in the treatment of cardiovascular and vascular disease, ranging from relatively simple catheters, balloons, and stents to complex mechanical systems such as ventricular assist devices (VADs). While antithrombotic and antiplatelet drugs, such as heparin and clopidogrel (Plavix), are commonly used to suppress biomaterial-induced thrombus formation for patients undergoing treatment with such devices, these types of drugs inhibit blood coagulation systemically, which can lead to other clinically significant bleeding-related complications. More effective treatments for cardiovascular and vascular disease would be provided from the development of thrombus-resistant biomaterials that would eliminate, or at least greatly reduce, the need for the use of systemic antithrombotic therapies. However, a limited understanding of the specific mechanisms underlying thrombotic reactions to synthetic materials following their contact with blood continues to hinder the development of new clinical devices and treatments for cardiovascular and vascular disorders. Addressing this problem requires the efforts of researchers and practitioners from diverse fields-in particular, this requires close interaction between biologists chemists, physicists, and engineers with clinical practitioners. The specific purpose of the BloodSurf 2016 Symposium (September 13-16, 2016, Babson Executive Conference Center, Wellesley, MA) is to bring together experts from these respective disciplines along with students and postdoctoral fellows who share a common interest in the development of thrombo-resistant biomaterials for four days immersed in presentations and discussions about the critical needs and research directions for the development of medical devices with improved blood compatibility. Recognizing the key role of platelets in mediating blood response to biomaterials and the need for closer integration with scientists and clinicians within the general hemostasis and thrombosis community, this symposium will be linked with the 9th Platelets International Symposium that is being coordinated by Dr. Alan D. Michelson, Director for Platelet Research Studies and Professor of Medicine, Harvard Medical School, and Dr. David Varon, Professor of Hematology, Hebrew University of Jerusalem. The Platelets International Symposium will follow BloodSurf 2016, including a one-day set of combined sessions. Because BloodSurf 2016 represents a unique meeting that falls outside of the normally scheduled set of professional conferences held each year, funding support is requested to offset the costs of attendance for our set of 16 invited speakers as well as providing eight student/postdoc travel awards (four of which will be set aside for the support of women, minorities, and persons with disabilities). Narrative: Biomaterial-induced thrombus formation is the number one clinical problem common to all blood-contacting medical devices that are used in the treatment of cardiovascular and vascular disease. The BloodSurf 2016 Symposium will bring together leading scientists, engineers, and clinicians interested in improving the blood compatibility of blood-contacting medical devices for four days of focused presentations and discussions. Funding support is requested to offset travel costs for our set of 16 invited speakers and to provide eight travel awards for students and postdoctoral fellows to attend this symposium.